Last reviewed · How we verify
NCT04763668: ARTMOMSBABES
Cardiometabolic Health of Children Exposed to Anti-retroviral Therapy (ART) in Utero
trial testing Pregnant HIV positive women on ARTs in In Utero Drug Exposure in 320 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Walter Sisulu University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 320 |
| Start date | 20 May 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across South Africa |
Drugs / interventions tested
- Pregnant HIV positive women on ARTs
- Babies born to HIV positive mothers on ARTs
Conditions studied
- In Utero Drug Exposure — all drugs for In Utero Drug Exposure →
Sponsor
Walter Sisulu University
Who can join
Eligibility, female only, with In Utero Drug Exposure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Human Immunodeficiency Virus (HIV) has been recently linked to increased risk for cardiovascular diseases (CVDs). The prevalence of cardiovascular diseases and its risk factor, hypertension, are very high in African communities especially in the working age group which also happens to have the bulk of young female adults in the reproductive age. Hypertension in African children is becoming a real cause for concern though its etiology remains elusive. Thanks to antiretroviral therapy (ART) use, many more infected persons live long enough to reproduce, consequently, an increasing number of children are being born to mothers who are infected with HIV. Could it be that in utero exposure of these children to HIV/ART contribute in programming them for increased risk for cardiovascular diseases thus making them more vulnerable to hypertension in childhood and adulthood? This study is aimed at exploring the possible association of in utero exposure to the HIV/ART environment and an increased risk for cardiovascular disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessment of the impact of HIV infection and anti-retroviral treatment on the cardiometabolic health of pregnant mothers and their offspring (ARTMOMSBABES).
Nkeh-Chungag BN, Engwa GA, Businge C, Mdondolo M, et al · · 2021 · cited 5× · PMID 34193034 · DOI 10.1186/s12872-021-02130-2
Verify or expand the search:
- PubMed search for NCT04763668
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Walter Sisulu University trials
Trials by the same sponsor.
- NCT05091827 — Cardiovascular Risk in Infants Exposed to Pre-eclampsia in Utero · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04763668 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Walter Sisulu University
- Last refreshed: 6 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04763668.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing